ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.

Tela Bio, a US-based surgical reconstruction technology developer backed by healthcare provider ProMedica and pharmaceutical firm Pacira Pharmaceuticals, filed on Tuesday to raise up to $69m in its initial public offering. Founded in 2012, Tela Bio provides soft tissue reinforcement materials for hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its implants have…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.